NCT05601830

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Clinical Study on the Safety and Efficacy of QN-030a in Acute Myeloid Leukemia With Minimal Residual Disease

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid Leukemia Minimal Residual Disease(AML MRD). This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-020a in patients with AML MRD, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.

Conditions

• Minimal Residual Disease

Interventions

Type	Name	Description
DRUG	QN-030a	NK cell therapy
DRUG	Cyclophosphamid	Lympho-conditioning Agent
DRUG	Fludarabine	Lympho-conditioning Agent
DRUG	Cytarabine	Lympho-conditioning Agent

Timeline

• Start date: 2022-10-09
• Primary completion: 2023-06-30
• Completion: 2023-06-30
• First posted: 2022-11-01
• Last updated: 2024-11-06

Locations

1 site across 1 country: China